The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
An article from
The fresh funds will support the biotech’s pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Published May 14, 2026
Getty Images
Cambridge-based Create Medicines announced Thursday it has raised another $122 million to bolster its cell therapy capabilities across cancers and autoimmune conditions.
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
A Series A, B and an IPO; Cabaletta reports CAR-T results
Antibody discovery platform Immunocan closes RMB250 million Series A · TechNode
The emerging cancer treatment that’s exciting scientists: ‘We’ve just scratched the surface on what’s possible’
BeOne wins FDA approval in lymphoma race
ASGCT dispatch: In vivo CAR-T is everywhere
Isomorphic Labs’ $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Alphabet’s Isomorphic Labs raises $2.1bn in Series B funding
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Five burning questions for Isomorphic after its mammoth $2B+ raise
